Bortezomib for neuromyelitis optica spectrum disorder: a new therapeutic option for the more severe forms? Does bortezomib inform our understanding of the immunology underlying neuromyelitis optica spectrum disorders?

MLA

Taylor, J., and Sr Irani. Bortezomib for Neuromyelitis Optica Spectrum Disorder: A New Therapeutic Option for the More Severe Forms? Does Bortezomib Inform Our Understanding of the Immunology Underlying Neuromyelitis Optica Spectrum Disorders? Oct. 2017. EBSCOhost, https://doi.org/10.1001/jamaneurol.2017.3447.

APA

Taylor, J., & Irani, S. (2017). Bortezomib for neuromyelitis optica spectrum disorder: a new therapeutic option for the more severe forms? Does bortezomib inform our understanding of the immunology underlying neuromyelitis optica spectrum disorders? https://doi.org/10.1001/jamaneurol.2017.3447

Chicago

Taylor, J, and Sr Irani. 2017. “Bortezomib for Neuromyelitis Optica Spectrum Disorder: A New Therapeutic Option for the More Severe Forms? Does Bortezomib Inform Our Understanding of the Immunology Underlying Neuromyelitis Optica Spectrum Disorders?,” October. doi:10.1001/jamaneurol.2017.3447.